New Mexico Psilocybin Pilot Status Report (as of May 2025)

Here’s a high-level rundown of where we’re at with our New Mexico psilocybin feasibility, safety and implementation pilot—a community-informed, Medicaid-aligned model of psychedelic-assisted care. What’s complete, what’s in motion, and what’s coming next.

Pilot Design

✅ Combination of individual and group psilocybin sessions finalized

  • Designed for both cost-efficiency and improved clinical effectiveness

🔄 Preparation and integration design currently underway through community engagement

🔄 Cost analysis framework drafted in partnership with UC Berkeley Center for the Economics of Psychedelics

Federal Approvals

✅ UNM secured DEA-approved facility for group psilocybin therapy research

🔄 IND (Investigational New Drug) application with Usona in process

  • Full draft submitted for external review on May 31, 2025

🔄 UNM–Usona Psilocybin Supply Agreement currently in negotiation

Fundrasing

🔄 $1M grant application submitted to Cohen Foundation

✅ $60K secured from Harris Family Foundation

  • Supports training for 3 peer navigator-facilitators (2 also receiving SNaP training)

✅ $135K received from Kindred Trust for community engagement and study community co-design

🔄 $250K–$500K in additional state funding currently under review

Training

🔄 3 veteran/first responder peer navigator-facilitators to be trained with Elementals in Colorado

🔄 2 of those will also train with SNaP Lab / Portland VA (July–August 2025)

✅ 2 UNM therapist-facilitators completed certification with CIIS and MAPS

Community Engagement & Health System Integration

🛠️ Bernalillo County Health Equity Council is leading the engagement strategy

  • Includes focus groups, set & setting design, provider engagement

🛠️ Fall 2025: Mapping support services available for preparation and integration

  • Review of Medicaid-covered services and Camden Coalition’s community preparation tool

🛠️ Final cohort group selection expected by Fall 2025

Pilot Implementation Timeline

📍 Recruitment Begins: October 2025 – Veterans & First Responders (Cohort 1)

📍 First Psilocybin Group Session: January 2026

📍 Second Session (Same Cohort): April 2026

📍 Third & Fourth Cohorts (e.g., women with PTSD/sexual trauma): TBD, based on community feedback

📍 Fifth Cohort (contingent on additional funding): TBD

📍 Outcomes & Feasibility Report: Q4 2026 – Q2 2027

  • Safety, cost comparison, adverse events, outcomes (PTSD/SUD), and support utilization

Policy Collaboration

✅ White paper and official medical use documentation completed

🔄 Ongoing policy work with NM DOH and state legislature

Pilot Advisors

  • Dr. Chris Stauffer (OHSU / VA Portland)

  • Kate Cooke (Southwestern College, Santa Fe)

  • Heroic Hearts Project: Armand LeComte & Jesse Gould

Previous
Previous

Advancing Standardized Care Metrics Across the Field